Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：1

作者：

Akula, Vinita ^{[1
]}

Chen, Lily ^{[1
]}

Acikgoz, Yusuf ^{[2
]}

Klein, Katherine ^{[1
]}

Yavuz, Betul Gok ^{[3
]}

Cevik, Lokman ^{[4
]}

Demir, Tarik ^{[5
]}

Manne, Ashish ^{[2
]}

Sahin, Ilyas ^{[6
]}

Kaseb, Ahmed ^{[7
]}

Hasanov, Elshad ^{[2
]}

机构：

[1] Univ Texas, Dept Internal Med, Hlth Sci Ctr, Houston UTHealth, Houston, TX USA

[2] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA

[3] Univ Missouri, Dept Med, Columbia, MO USA

[4] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH USA

[5] Northwestern Univ, Div Hematol & Oncol Dev Therapeut Inst, Chicago, IL USA

[6] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA

[7] Univ Texas, Dept Gastrointestinal Med Oncol, MD Anderson Canc Ctr, Houston, TX USA

来源：

NPJ PRECISION ONCOLOGY | 2025年 / 9卷 / 01期

关键词：

CAMRELIZUMAB PLUS APATINIB; OPEN-LABEL; DOUBLE-BLIND; SINGLE-ARM; RECURRENCE; RESECTION; SORAFENIB; CANCER; TRIAL; HCC;

D O I：

10.1038/s41698-025-00846-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

页数：13

共 50 条

[1] Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Longo, Vito
Brunetti, Oronzo
Gnoni, Antonio
Licchetta, Antonella
Delcuratolo, Sabina
Memeo, Riccardo
Solimando, Antonio Giovanni
Argentiero, Antonella
MEDICINA-LITHUANIA, 2019, 55 (10):
[2] Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
Akbulut, Zeynep
Aru, Basak
Aydin, Furkan
Demirel, Gulderen Yanikkaya
FRONTIERS IN IMMUNOLOGY, 2024, 15
[3] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
van Doorn, Diederick J.
Takkenberg, Robert Bart
Klumpen, Heinz-Josef
PHARMACEUTICALS, 2021, 14 (01) : 1 - 23
[4] Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Zhao, Mei
Chen, Shanwen
Li, Conggui
Du, Yingying
Li, Ping
CANCERS, 2023, 15 (03)
[5] Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review
Tian, Chunhong
Yu, Yifan
Wang, Yuqing
Yang, Lunwei
Tang, Ying
Yu, Chengyang
Feng, Gaofei
Zheng, Dayong
Wang, Xiongwen
FRONTIERS IN IMMUNOLOGY, 2024, 15
[6] Immune checkpoint inhibitors for hepatocellular carcinoma
El Dika, Imane
Khalil, Danny N.
Abou-Alfa, Ghassan K.
CANCER, 2019, 125 (19) : 3312 - 3319
[7] The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
Wang, Yun
Jiang, Man
Zhu, Jingjuan
Qu, Jialin
Qin, Kang
Zhao, Deze
Wang, Li
Dong, Lina
Zhang, Xiaochun
BIOMEDICINE & PHARMACOTHERAPY, 2020, 132
[8] Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
Ouyang, Tao
Kan, Xuefeng
Zheng, Chuansheng
FRONTIERS IN ONCOLOGY, 2022, 12
[9] Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma
Ruff, Samantha M.
Pawlik, Timothy M.
HEPATOMA RESEARCH, 2024, 10
[10] Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Abd El Aziz, Mohamed A.
Facciorusso, Antonio
Nayfeh, Tarek
Saadi, Samer
Elnaggar, Mohamed
Cotsoglou, Christian
Sacco, Rodolfo
VACCINES, 2020, 8 (04) : 1 - 19

← 1 2 3 4 5 →